A phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR mutated non-small cell lung cancer

Trial Profile

A phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR mutated non-small cell lung cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Capmatinib (Primary) ; Nazartinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 19 Jul 2017 Planned End Date changed from 3 Jun 2019 to 23 Dec 2018.
    • 19 Jul 2017 Planned primary completion date changed from 3 Jun 2019 to 29 Jun 2018.
    • 23 Feb 2017 Planned number of patients changed from 118 to 130.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top